Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Medtronic
Harvard Business School
Mallinckrodt
AstraZeneca

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR DIGOXIN PEDIATRIC


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Digoxin Pediatric

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000476 ↗ Digitalis Investigation Group (DIG) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1990-06-01 To determine if digitalis had a beneficial, harmful, or no effect on total mortality in patients with clinical heart failure and sinus rhythm.
NCT00000547 ↗ Enalapril After Anthracycline Cardiotoxicity Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1994-04-01 To determine if the chronic administration of enalapril, an inhibitor of angiotensin converting enzyme (ACE), reduces progression of cardiac dysfunction in pediatric oncology patients who have received anthracyclines, and who are not currently on digoxin, diuretics, or vasodilators for heart failure.
NCT00000556 ↗ Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1995-03-01 To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.
NCT00006330 ↗ Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn Completed National Center for Research Resources (NCRR) N/A 1969-12-31 Hawthorn (Crataegus oxyacantha) is a natural product that is popular in European and American herbal medicine practice. Some of its cardiac uses include the treatment of high and low blood pressure, rapid heart beat, chest pain, and blocked arteries. In many cases, it is used as an adjuvant agent with other cardiac drugs such as digoxin, amiodarone, and warfarin. To date, little information is known about the effect of hawthorn when taken with other drugs and if toxicities occur when hawthorn is used with other drugs. The purpose of this study is to examine the interaction between digoxin and hawthorn in eight healthy subjects. Subjects will be recruited by advertisement. The design of the study will include a 10-day and a three-week treatment phase of digoxin 0.125 mg - 0.25 mg/day and hawthorn (Crataegus special extract WS1442, Schwabe Co.) 450 mg twice daily or placebo, with a randomized crossover. There will be a three-week washout period in between treatment phases. On day 10 (phase I) and day 21 (phase II), subjects will have 12 blood samples drawn for pharmacokinetic analysis. The plasma samples will be measured for digoxin concentration. Additionally, the subjects will be assessed for any clinical toxicities or adverse events. The significance of this study is to provide the clinician with information regarding the safe use of digoxin in combination with the herbal supplement, hawthorn.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Digoxin Pediatric

Condition Name

Condition Name for Digoxin Pediatric
Intervention Trials
Healthy 35
Atrial Fibrillation 16
Heart Failure 12
Healthy Volunteers 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Digoxin Pediatric
Intervention Trials
Atrial Fibrillation 24
Heart Failure 22
Breast Neoplasms 5
Arthritis, Rheumatoid 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Digoxin Pediatric

Trials by Country

Trials by Country for Digoxin Pediatric
Location Trials
United States 167
Germany 22
Canada 18
Japan 12
United Kingdom 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Digoxin Pediatric
Location Trials
Texas 23
California 11
Florida 11
Ohio 10
New York 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Digoxin Pediatric

Clinical Trial Phase

Clinical Trial Phase for Digoxin Pediatric
Clinical Trial Phase Trials
Phase 4 25
Phase 3 18
Phase 2/Phase 3 3
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Digoxin Pediatric
Clinical Trial Phase Trials
Completed 134
Recruiting 22
Not yet recruiting 18
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Digoxin Pediatric

Sponsor Name

Sponsor Name for Digoxin Pediatric
Sponsor Trials
Boehringer Ingelheim 13
Bristol-Myers Squibb 10
AstraZeneca 7
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Digoxin Pediatric
Sponsor Trials
Other 170
Industry 134
NIH 12
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Mallinckrodt
McKinsey
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.